Research Study

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial
Principal Investigator 
Anthony Y-F. Fung

Overview

Body Locations and Systems 
Arteries
ClinicalTrials.gov# 
NCT02525939
Status 
Recruiting
Study Start/End 
Apr 1, 2016 to Apr 1, 2022
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Andrew Starovoytov, Research Coordinator
Phone 
604-875-5079
Email Address 
a.starovoytov@ubc.ca
Purpose of Study 

A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.